Publications by authors named "D Krasnozhon"
Purpose: Dr Reddy's Laboratories Trastuzumab (DRL_TZ) is a biosimilar to Herceptin under development. The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the reference medicinal product (RMP) along with concomitant weekly paclitaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
Methods: This was a randomized, double-blind study in female patients with HER2-positive MBC, randomly assigned in a 1:1 ratio to receive either DRL_TZ or the RMP, that is, an innovator product sourced from the European region, along with additional chemotherapy, as first-line treatment for up to 24 weeks.
Article Synopsis
- The study aimed to assess the safety and effectiveness of efbemalenograstim alfa for boosting neutrophil levels in breast cancer patients receiving chemotherapy, focusing on a phase 2 trial.
- A total of 232 patients were treated with different chemotherapy regimens and randomized to receive either efbemalenograstim alfa or pegfilgrastim, with results indicating efbemalenograstim alfa showed comparable outcomes to pegfilgrastim in managing neutropenia.
- The findings revealed that efbemalenograstim alfa had a similar safety profile to pegfilgrastim, with low instances of febrile neutropenia, suggesting it could be a viable option for neutrophil support during chemotherapy.
Aim: Late radiation injury in the form of radiation-induced fibrosis (RIF) is one of the many complications of radiation therapy. The aim was to evaluate oxygen perfusion in the skin in the area of late radiation injury manifested as RIF in patients with breast cancer.
Materials And Methods: Based on our first-hand experience in treating late radiation injures of soft tissues in patients with breast cancer, we measured oxygen perfusion of the skin (tсрО2) in the area of late radiation injury using a transcutaneous monitor (oximeter) TCM 400 (Radiometer, Denmark).
Vacuum ultraviolet excitation luminescence spectroscopy of few-layered MoS2.
J Phys Condens Matter
January 2016
We report on vacuum ultraviolet (VUV) excited photoluminescence (PL) spectra emitted from a chemical vapor deposited MoS2 few-layered film. The excitation spectrum was recorded by monitoring intensities of PL spectra at ~1.9 eV.
View Article and Find Full Text PDFBackground: Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed reference product, Neupogen(®), in breast cancer patients receiving (neo)adjuvant myelosuppressive chemotherapy (TAC).
Patients And Methods: A total of 218 patients receiving 5 µg/kg/day filgrastim over six chemotherapy cycles were randomized 1:1:1:1 into four arms.